SLRX

Salarius Pharmaceuticals, Inc. (SLRX) | Rumor.io

Salarius Pharmaceuticals

SLRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)70%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SLRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 13

$SLRX has traded 21 million shares on a 4 million share float before the opening bell.
With Gates funding, $SLRX valuation is expected to be through the roof.
$SLRX has agreed with the Gates Foundation for production, and is considered seriously undervalued.

Generated by AI

Sentiment

Of the messages about SLRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.92% +1.64
Bearish	—	—	—	14.08% -1.64

Bullish· Jan 13

$SLRX has a strong hold, with the potential to reach $5.
The company's agreement with the Gates Foundation for production has made the stock undervalued, with a valuation "thru the roof".
The stock has seen significant gains, with some users reporting 80% returns, and is expected to continue to rise, with some predicting a price of $10.

Bearish· Jan 13

The company has been involved in several controversies, including a change of leadership and an increase in shares, which may be contributing to the stock's decline.
The stock has been heavily shorted, and the shorts may be struggling to cover their positions, leading to a potential collapse in the stock's price.
The stock has been unable to break through key resistance levels, including its VWAP, and has instead been subject to significant price drops and volume, suggesting that it may be experiencing a strong bearish trend.

Generated by AI

Topics

Of the messages about SLRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	10.19%
Announcements	—	—	—	44.58%
Controversies	—	—	—	1.13%
Earnings	—	—	—	0.4%
Macro	—	—	—	5.5%
Technical Analysis	—	—	—	38.19%

Announcements· Nov 12

Salarius Pharmaceuticals, Inc. (SLRX) expects its merger with Decoy Therapeutics to close on or around November 12, 2025, contingent upon the completion of a $7 million public offering.
The $7 million public offering has been priced, with Salarius Pharmaceuticals issuing 2,514,335 shares of common stock and pre-funded warrants to purchase 2,152,331 shares of common stock.
Salarius Pharmaceuticals' letetresgene autoleucel (lete-cel) has been granted breakthrough therapy designation by the FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS).

Technical Analysis· Nov 12

$SLRX has seen a massive pullback, with an entry point at 1.55, and a great pivot from the lows.
The stock's trendline must hold above VWAP ~2.03 for a move higher, with key levels at 2.01, 2.17, and 2.33.
A break above 2.20 could trigger a short squeeze, but the stock lacks strength and may fall back below 1.20.

Generated by AI

Community

Of the messages about SLRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	32.64%
Newcomers	—	—	—	67.36%

Regulars· Nov 19

Salarius Pharmaceuticals has cited errors on the S&P CapIQ platform following its merger with Decoy Therapeutics.
The company's shares continue to trade on the Nasdaq stock market under the symbol "SLRX".
The merger appears to have had no impact on the trading of SLRX shares on the Nasdaq stock market.

Newcomers· Nov 12

A newcomer is excited about the potential of Salarius Pharmaceuticals, Inc. ($SLRX) to reach $3.00, a 136% increase from $1.26, and believes it will be a rebound stock.
Another newcomer is monitoring the top gappers in the market, with $SLRX being one of them, but notes that none have increased by more than 100% so far.
A newcomer claims to have called $SLRX correctly, which has increased by over 200%, and suggests that another stock, $CJET, may be the next big riser.

Generated by AI

Also Discussed

Investors talking about SLRX also mention

#	Name	Attention
1	Stabilis Solutions Inc.SLNG	0%0
2	Legacy Education Inc.LGCY	0%new
3	FPAY - FlexShopper, Inc.	——
4	Protara Therapeutics, Inc.TARA	0%0
5	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
6	OBLN - Obalon Therapeutics, Inc.	——
7	Immunic, Inc.IMUX	0%0
8	Alpha Metallurgical Resources, Inc.AMR	0%0
9	Fuwei Films Holdings Co LtdFFHL	0%new
10	NovaBay Pharmaceuticals, Inc.NBY	0%0